Antipsychotics continue to have a place in the management of difficult behavior problems in patients with dementia

Journal of the American Medical Directors Association

Volumn 14, Issue 6, 2013, Pages 447-449

  Jennings, Leigh ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BATH; BEHAVIOR DISORDER; DAILY LIFE ACTIVITY; DELUSION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG PACKAGING; GERIATRIC PATIENT; GOVERNMENT REGULATION; HUMAN; LETTER; MEDICAID; MEDICAL DOCUMENTATION; MEDICARE; META ANALYSIS (TOPIC); MOOD DISORDER; MORTALITY; NURSING HOME; NURSING STAFF; PARKINSONISM; PATIENT RIGHT; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS;

EID: 84878890462     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2013.03.015     Document Type: Letter

References (32)

1. CMS's stated goal is to reduce overall antipsychotic use in nursing homes from 23.9% to 20.3% by the end of 2012. This excludes patients with schizophrenia, Huntington's disease, and Tourette's disorder. Available at: Accessed January 20, 2013. http://www.cms.gov/Medicare/Provider.Enrollment%2dand%2dCertification/CertificationandComplianc/Downloads/AntipsychoticMedicationQM.pdf.
2. Requirements for nursing facilities. 42 USC § 1396r. Available at: Accessed February 24, 2013. http://www.law.cornell.edu/uscode/text/42/1396r.
3. Food and Drug Administration. Public health advisory: Deaths with antipsychotics in elderly patients with dementia. Available at: Accessed February 24, 2013. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm.
4. Food and Drug Administration. FDA requests boxed warning on older class of antipsychotic drugs. Available at: Accessed February 24, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm.
5. Levinson DR. Department of Health and Human Services, Office of Inspector General. Medicare atypical antipsychotic drug claims for elderly nursing home residents. May 2011. Available at: Accessed January 20, 2013. https://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf.
6. Harris G. Antipsychotic drugs called hazardous for the elderly. New York Times, May 9, 2011. Available at: Accessed January 26, 2013. http://www.nytimes.com/2011/05/10/health/policy/10drug.html.
7. American Society of Consultant Pharmacists. Policy statement: Use of antipsychotic medications in nursing facility residents. Available at: Accessed January 26, 2013. https://www.ascp.com/sites/default/files/ASCP-antipsychotics-statement.pdf.
8. Alzheimer's Association. Challenging behaviors. Available at: Accessed January 20, 2013. http://www.alz.org/documents_custom/statements/challenging_behaviors.pdf.
9. Carlat D. In defense of antipsychotics for dementia. Available at: Accessed January 13, 2013. http://www.cnn.com/2011/OPINION/05/31/carlat.nursin.home.drugs/index.html.
10. Allen J.E. Nursing Home Federal Requirements: Guidelines to Surveyors and Survey Protocols 2003, Springer Publishing Company, New York. 5th ed.
11. Ballard C.G., Waite J., Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006, (1):CD003476.
12. Maher A.R., Maglione M., Bagley S., et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011, 306:1359-1369.
13. Schneider L.S., Tariot P.N., Dagerman K.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006, 355:1525-1538.
14. Ballard C., Lana M.M., Theodoulou M., et al. A randomized blinded placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PloS Med 2008, 5:e76.
15. Cohen-Mansfield J., Lipson S., Werner P., et al. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 1999, 159:1733-1740.
16. Ballard C.G., Thomas A., Fossey J., et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004, 65:114-119.
17. VanDelinder B. Appropriate use of antipsychotics in the nursing home. Webinar. Available at: Accessed February 28, 2013. http://www.ndhcri.org/Healthcare_Professionals/HAC/antipsychoticmeds/ndhcri_antipsych_webinar(BV).pdf.
18. Devanand D.P., Mintzer J., Schultz S.K., et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012, 367:1497-1507.
19. Schneider L.S., Dagerman K.S., Insel P., et al. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294:1934-1943.
20. Vigen C.L.P., Mack W.J., Keefe R.S.E., et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from the CATIE-AD. Am J Psychiatry 2011, 168:831-839.
21. Sultzer D.L., Davis S.M., Tariot P.N., et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD Effectiveness Trial. Am J Psychiatry 2008, 165:844-854.
22. Jalbert J.J., Eaton C.B., Miller S.C. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010, 11:120-127.
23. Lonergan E., Luxenberg J., Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002, 2:CD002852.
24. Kales H.C., Kim H.M., Zivin K., et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012, 169:71-79.
25. Desai A.K., Grossberg G.T. Psychosocial and environmental interventions. Psychiatric Consultation in Long-Term Care: A Guide for Health Care Professionals 2010, The John Hopkins University Press, Baltimore.
26. Wells D.L., Dawson P., Sidani S., et al. Effects of an abilities-focused program of morning care on residents who have dementia and on caregivers. J Am Geriatr Soc 2000, 20:301-314.
27. O'Connor D.W., Ames D., Bardner B., et al. Psychosocial treatments of behavioral symptoms in dementia: a systematic review of reports meeting quality standards. International Psychogeriatrics 2009, 21:225-240.
28. Span P. Clearing the fog in nursing homes. The New York Times. Available at: Accessed January 20, 2013. http://newoldage.blogs.nytimes.com/2011/02/15/clearing-the-fog-in-nursing-homes.
29. Brodaty H., Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012, 169:946-953.
30. Morley J.E. Antipsychotics and dementia: a time for restraint?. J Am Med Dir Assoc 2012, 13:761-763.
31. Desai A.K., McFadden S.H. Reducing antipsychotic use in long term care residents: Addressing psychological and spiritual needs of residents with dementia is crucial. J Am Med Dir Assoc Assoc 2013, 14:224-225.
32. Desai AK. Bringing it together. Paper presented at: Pharmacologic and Non-pharmacologic Management of Behavioral and Psychological Symptoms of Dementia; March 2, 2013; Saint Louis University, St. Louis, MO.